ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $3,860,000 | +37.1% | 22,430 | 0.0% | 0.02% | +41.7% |
Q2 2021 | $2,815,000 | -7.5% | 22,430 | 0.0% | 0.01% | -7.7% |
Q1 2021 | $3,042,000 | +6.0% | 22,430 | 0.0% | 0.01% | +18.2% |
Q4 2020 | $2,870,000 | -0.5% | 22,430 | -12.5% | 0.01% | -8.3% |
Q3 2020 | $2,885,000 | +12.2% | 25,640 | -5.0% | 0.01% | +9.1% |
Q2 2020 | $2,572,000 | +6.0% | 27,000 | 0.0% | 0.01% | -26.7% |
Q1 2020 | $2,426,000 | -26.8% | 27,000 | -67.8% | 0.02% | -34.8% |
Q3 2019 | $3,315,000 | -3.8% | 83,900 | 0.0% | 0.02% | 0.0% |
Q2 2019 | $3,447,000 | -11.8% | 83,900 | 0.0% | 0.02% | -8.0% |
Q1 2019 | $3,907,000 | +6.9% | 83,900 | 0.0% | 0.02% | -16.7% |
Q4 2018 | $3,654,000 | -23.9% | 83,900 | 0.0% | 0.03% | -6.2% |
Q3 2018 | $4,802,000 | -39.6% | 83,900 | -48.8% | 0.03% | -46.7% |
Q2 2018 | $7,952,000 | +24.1% | 163,900 | 0.0% | 0.06% | +11.1% |
Q1 2018 | $6,408,000 | -7.9% | 163,900 | 0.0% | 0.05% | -10.0% |
Q4 2017 | $6,956,000 | +13.7% | 163,900 | 0.0% | 0.06% | +20.0% |
Q3 2017 | $6,117,000 | +599.9% | 163,900 | +469.8% | 0.05% | +525.0% |
Q2 2017 | $874,000 | +14.8% | 28,765 | 0.0% | 0.01% | +33.3% |
Q1 2017 | $761,000 | +3.7% | 28,765 | 0.0% | 0.01% | -14.3% |
Q4 2016 | $734,000 | -29.5% | 28,765 | 0.0% | 0.01% | -22.2% |
Q3 2016 | $1,041,000 | +6.6% | 28,765 | 0.0% | 0.01% | -10.0% |
Q2 2016 | $977,000 | +28.7% | 28,765 | 0.0% | 0.01% | +25.0% |
Q1 2016 | $759,000 | -45.9% | 28,765 | 0.0% | 0.01% | -33.3% |
Q4 2015 | $1,403,000 | +95.9% | 28,765 | 0.0% | 0.01% | +71.4% |
Q3 2015 | $716,000 | -21.3% | 28,765 | 0.0% | 0.01% | -12.5% |
Q2 2015 | $910,000 | -16.9% | 28,765 | 0.0% | 0.01% | -11.1% |
Q1 2015 | $1,095,000 | -2.3% | 28,765 | 0.0% | 0.01% | -18.2% |
Q4 2014 | $1,121,000 | +28.9% | 28,765 | 0.0% | 0.01% | 0.0% |
Q3 2014 | $870,000 | -11.0% | 28,765 | 0.0% | 0.01% | -8.3% |
Q2 2014 | $977,000 | -1.5% | 28,765 | 0.0% | 0.01% | -7.7% |
Q1 2014 | $992,000 | -16.5% | 28,765 | -4.1% | 0.01% | -23.5% |
Q4 2013 | $1,188,000 | – | 30,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |